Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex­pands on­col­o­gy col­lab

Af­ter the FDA ap­proved Re­vance’s Daxxi­fy as a longer-last­ing al­ter­na­tive to Ab­b­Vie’s cash cow Botox, Re­vance is look­ing to top off its cof­fers.

The aes­thet­ics com­pa­ny is of­fer­ing 8 mil­lion shares of its com­mon stock, priced at $25 a piece, for a to­tal ex­pect­ed raise of $200 mil­lion in gross earn­ings. Un­der­writ­ers, ac­cord­ing to Re­vance, get 30 days to get an ad­di­tion­al 1.2 mil­lion shares.

The of­fer­ing is ex­pect­ed to close on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER